Response to Ansell et al. “Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel”

Note: The review process for this paper was fully handled by Christian Weber, Editor in Chief.

• References

• 1 Ansell J, Crowther M, Burnett A. et al. Letter to the Editor. Thromb Haemost 2014; 112: 841.
• 2 Lip GYH, Camm J, Hylek EM. et al. Non-vitamin K antagonist oral anticoagulants. An appeal for concensus on terminology. Chest 2014; 145: 1177-1178.
• 3 Majeed A, Hwang HG, Connolly SJ. et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 2013; 128: 2325-2332.
• 4 De Caterina R, Husted S, Wallentin L. et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110: 1087-1107.
• 5 De Caterina R, Husted S, Wallentin L. et al. European Society of Cardiology Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 109: 569-579.